Clinical Studies - GRAIL

Background image

Background texture

Our clinical study program

We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection technologies. To support and validate our technology, we are partnering with leading community and academic medical centers around the world.

Clinical studies

REACH/Galleri-Medicare Study

This multi-center comparative, prospective, cohort study is designed to assess the real world clinical impact, including safety and test performance, of the Galleri® test.

PATHFINDER 2 Study

This is a prospective, multi-center interventional study of the Galleri® multi-cancer early detection test with return of test results for participants enrolled through healthcare systems in North America.

REFLECTION Study

An observational study of patients who have been administered the Galleri® test.

NHS-Galleri Trial

A prospective, randomized, controlled trial to assess the performance and clinical utility of the Galleri® test for population screening in the UK when added to standard of care.

A prospective, observational, longitudinal, cohort study in London, United Kingdom. The study is designed to enroll approximately 13,000 men and women who do not have a high risk for lung or other cancer due to significant smoking history at the time of enrollment.

A prospective, observational, longitudinal, cohort study that enrolled approximately 100,000 women to refine the predictive ability of the Galleri® test to detect invasive cancers.

The Circulating Cell-free Genome Atlas (CCGA) Study

A multicenter, prospective, case-control, observational, longitudinal study designed to identify the best performing assay and then determine whether genome-wide cfDNA methylation sequencing in combination with machine learning could distinguish cancer from non-cancer and localize a signal shared by a large number of cancers.

PATHFINDER Study

A prospective, interventional, return-of-results, multi-center study to assess the implementation of an earlier version of the Galleri® multi-cancer early detection (MCED) test in a clinical setting. Later, blood samples were reanalyzed with the current version of Galleri.